-
Mashup Score: 385 Lessons from Stanford's COVID Conference - 4 hour(s) ago
On Friday, I spoke at Stanford, discussing lessons from the COVID19 pandemic.
Source: www.drvinayprasad.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 985 Lessons from Stanford's COVID Conference - 10 hour(s) ago
On Friday, I spoke at Stanford, discussing lessons from the COVID19 pandemic.
Source: www.drvinayprasad.comCategories: General Medicine News, Hem/OncsTweet-
5 lessons from Stanford's policy conference https://t.co/1iVUsZktx7
-
-
Mashup Score: 15Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused? - PubMed - 15 hour(s) ago
The use of surrogate outcomes should be limited to situations where a surrogate has demonstrated robust ability to predict meaningful benefits, or where cases are dire, rare or with few treatment options. In both cases, surrogates must be used only when continuing studies examining hard endpoints ha …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet-
https://t.co/7D5DddiKPK
-
-
Mashup Score: 29Public Health Sex Party Hypocrisy | The VPZD Show Ep. 35 - 1 day(s) ago
Former New York public health official Jay Varma’s hypocritical sex parties during COVID, why we refuse to talk to most reporters, VP’s take on the new schiz…
Source: www.youtube.comCategories: General Medicine News, Hem/OncsTweet-
Episode 35 https://t.co/ZStZ62sswN
-
-
Mashup Score: 525LIVE from Stanford - 3 day(s) ago
Pandemic recap
Source: www.drvinayprasad.comCategories: General Medicine News, Hem/OncsTweet-
Live from the Stanford health policy confidence. https://t.co/MDTrxiK915
-
-
Mashup Score: 525LIVE from Stanford - 3 day(s) ago
Pandemic recap
Source: www.drvinayprasad.comCategories: General Medicine News, Hem/OncsTweet-
Live from the Stanford health policy confidence. https://t.co/MDTrxiK915
-
-
Mashup Score: 82
Vinay Prasad, MD MPH; Physician & Professor Hematologist/ OncologistProfessor of Epidemiology, Biostatistics and MedicineAuthor of 500+ Peer Reviewed papers,…
Source: www.youtube.comCategories: General Medicine News, Hem/OncsTweet-
No vax, no transplant? https://t.co/oXQlq8t4aq
-
-
Mashup Score: 3Reporting of Postprotocol Therapies and Attrition in Multiple Myeloma Randomized Clinical Trials: A Systematic Review - 4 day(s) ago
What proportion of multiple myeloma randomized clinical trials report postprotocol therapies, and when reported, how do these therapies compare with existing standard of care?In this systematic review of 103 randomized clinical trials including 47 251 …
Source: www.ncbi.nlm.nih.govCategories: General Medicine News, Expert PicksTweet-
7 Trials have really bad post-protocol care https://t.co/Aoi4VCp39Q
-
-
Mashup Score: 4Frontiers | Multiple myeloma: challenges with deciding the optimal sequencing strategy - 4 day(s) ago
The therapeutic landscape for multiple myeloma (MM) has witnessed great advances over the past two decades, with 19 FDA-approved drugs currently available. T…
Source: www.frontiersin.orgCategories: General Medicine News, Expert PicksTweet-
8 Imagine a world where to move myeloma drugs upfront you needed OS with good control and good post protocol care. Those trials WOULD take a long time, and here is the rub, they MIGHT EVEN be negative. https://t.co/cvIsnwEfZL
-
-
Mashup Score: 8
Ixazomib maintenance prolongs PFS and represents an additional option for post-transplant maintenance therapy in patients with newly diagnosed multiple myeloma.
Source: www.thelancet.comCategories: General Medicine News, Expert PicksTweet-
In the current system, PFS is accepted to move to earlier lines and companies get REGULAR approval for it. So again, AA can't be credited with lives saved here. 6 But current landscape has issues-Trials have bad control arms; like Vincents's study of ixa https://t.co/Ghzop0TVhX
-
5 lessons from Stanford's policy conference https://t.co/1iVUsZktx7